New mRNA shot targets Hard-to-Treat cancers in early human test
NCT ID NCT07562815
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new mRNA medicine (NCP-IL-22BP mRNA) in 9 people with advanced solid tumors that have not responded to standard treatments. The medicine is injected directly into tumors to help the body fight cancer. The main goal is to check safety and find the right dose, with a secondary look at whether tumors shrink.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOFT TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital
Chengdu, Sichuan, 610000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Digital peer support: a new weapon against cancer treatment anxiety?
- Could sitting up make radiation therapy more comfortable?
- Can we predict dangerous side effects when combining radiation and immunotherapy?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Family history as a shield: can culturally tailored guidance cut cancer risk?